Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas by Huo, D. et al.
IMPORTANCE African Americans have the highest breast cancer mortality rate. Although racial
difference in the distribution of intrinsic subtypes of breast cancer is known, it is unclear if
there are other inherent genomic differences that contribute to the survival disparities.
OBJECTIVES To investigate racial differences in breast cancer molecular features and survival
and to estimate the heritability of breast cancer subtypes.
DESIGN, SETTING, AND PARTICIPANTS Among a convenience cohort of patients with invasive
breast cancer, breast tumor and matched normal tissue sample data (as of September 18,
2015) were obtained from The Cancer Genome Atlas.
MAIN OUTCOMES AND MEASURES Breast cancer–free interval, tumor molecular features, and
genetic variants.
RESULTS Participants were 930 patients with breast cancer, including 154 black patients of
African ancestry (mean [SD] age at diagnosis, 55.66 [13.01] years; 98.1% [n = 151] female) and
776 white patients of European ancestry (mean [SD] age at diagnosis, 59.51 [13.11] years;
99.0% [n = 768] female). Compared with white patients, black patients had a worse breast
cancer-free interval (hazard ratio, HR=1.67; 95% CI, 1.02-2.74; P = .043). They had a higher
likelihood of basal-like (odds ratio, 3.80; 95% CI, 2.46-5.87; P < .001) and human epidermal
growth factor receptor 2 (ERBB2 [formerly HER2])–enriched (odds ratio, 2.22; 95% CI,
1.10-4.47; P = .027) breast cancer subtypes, with the Luminal A subtype as the reference.
Blacks had more TP53 mutations and fewer PIK3CA mutations than whites. While most
molecular differences were eliminated after adjusting for intrinsic subtype, the study found
16 DNA methylation probes, 4 DNA copy number segments, 1 protein, and 142 genes that
were differentially expressed, with the gene-based signature having an excellent capacity for
distinguishing breast tumors from black vs white patients (cross-validation C index, 0.878).
Using germline genotypes, the heritability of breast cancer subtypes (basal vs nonbasal) was
estimated to be 0.436 (P = 1.5 × 10−14). The estrogen receptor–positive polygenic risk score
built from 89 known susceptibility variants was higher in blacks than in whites (difference,
0.24; P = 2.3 × 10−5), while the estrogen receptor–negative polygenic risk score was much
higher in blacks than in whites (difference, 0.48; P = 2.8 × 10−11).
CONCLUSIONS AND RELEVANCE On the molecular level, after adjusting for intrinsic subtype
frequency differences, this study found a modest number of genomic differences but a
significant clinical survival outcome difference between blacks and whites in The Cancer
Genome Atlas data set. Moreover, more than 40% of breast cancer subtype frequency
differences could be explained by genetic variants. These data could form the basis for the
development of molecular targeted therapies to improve clinical outcomes for the specific
subtypes of breast cancers that disproportionately affect black women. Findings also indicate
that personalized risk assessment and optimal treatment could reduce deaths from
aggressive breast cancers for black women.
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B reast cancer is the most common tumor in women.1,2While the incidence among black and white womenin the United States has converged at 135 cases per
100 000 women per year in recent years, the mortality gap has
continued to increase, with a 42% higher death rate in black
patients.3 The reasons for this survival gap are multifactorial
and may include access to care and inherent biological tumor
differences.4 One known biological cause of this racial dispar-
ity is the higher frequency of basal-like or triple-negative breast
cancers (TNBCs) (ie, negative for estrogen receptor [ER], pro-
gesterone receptor, and human epidermal growth factor re-
ceptor 2 [ERBB2, formerly HER2]) among black women.5-10
However, there is a paucity of data on additional biological or
genomic differences that explain the higher mortality rate in
blacks. Increased genetic predisposition due to higher risk al-
lele frequencies at the TERT (OMIM 187270) locus and a higher
prevalence of specific lifestyle factors, such as lack of breast-
feeding, may contribute to intrinsic subtype frequency differ-
ences seen across ethnicities.11,12
To address this knowledge gap, we systematically inves-
tigated molecular features, including gene expression, pro-
tein expression, somatic mutations, somatic DNA copy num-
ber alteration (CNA), and DNA methylation patterns, between
breast cancers of black and white patients and examined dif-
ferences in breast cancer recurrence and overall survival in re-
lation to these molecular features. In addition, we assessed
germline genetic variants for breast cancer intrinsic subtypes
and estimated the heritability of these subtypes.
Methods
Study Cohort
This study used breast cancer data (as of September 18, 2015)
from The Cancer Genome Atlas (TCGA), which are publicly
available from TCGA Data Portal (https://tcga-data.nci.nih.gov
/docs/publications/tcga/). Data fields were processed using
established methods unless otherwise specified13 (eTable 1 in
Supplement 1). We estimated genomic race using principal
component analysis of germline genotype data from 1062
patients (eMethods in Supplement 2). Patients were grouped
into genomic black (≥50% African ancestry) or genomic white
(≥90% European ancestry). Herein, we present analytical
methods unique to this study, while genomic data generation
and processing have been previously described.14 The samples
were collected under institutional review board–approved
protocols at each participating institution and analysis was
performed by the African American TCGA Breast Cancer
Working Group. This study used only deidentified data from
TCGA Project.
Gene Expression by RNA Sequencing
After excluding genes not expressed or not variable (zero reads
or SD<1), upper quartile normalized RNA sequencing data were
log2 transformed. Prediction analysis of microarray 50 (PAM50)
intrinsic subtypes were called as previously described.14,15 Mul-
tinomial logistic regression was used to examine the associa-
tion between breast cancer subtype and genomic race.
Differentially expressed genes between black patients and
white patients were identified by linear regression, fitting a
model adjusting for age at diagnosis and batch (36 batches) and
further adjusting for intrinsic subtype. False discovery rates
(FDRs) by Benjamini-Hochberg and Bonferroni-adjusted P val-
ues were calculated to control for multiple testing. Hierarchi-
cal clustering analysis with a Spearman rank correlation simi-
larity measure was used for visualization. We used elastic net
penalized logistic regression to create a race-differentiated
gene signature, with cross-validation to tune the penalty
parameters.16 Using 10-fold cross-validation data sets, area
under the receiver operating characteristic curve, ie, C index
(AUROC), was calculated to assess the discriminating capac-
ity of the signature.
Protein Expression
Reverse phase protein array data contain expression levels for
215 proteins and phosphorylated proteins for 745 patients (114
black and 631 white). Linear regression models were used to
identify differentially expressed proteins, adjusting for age at
diagnosis and batches. Proteins that passed the multiple test-
ing correction with FDRs less than 0.05 were included in a mul-
tivariable logistic regression. AUROC was calculated using
10-fold cross-validation data sets.
Somatic Mutation and DNA CNAs
We examined genes with mutations in coding regions,14 inte-
grating information from DNA and RNA sequencing.17 The
numbers of mutated genes and CNA segments per patient were
compared between blacks and whites using Wilcoxon rank sum
tests. Recurrently mutated genes and recurrent CNAs were
identified by MutSigCV2 and GISTIC,18,19 respectively. Differ-
ences in mutation frequency or CNAs were determined with
Fisher exact test and logistic regression to adjust for subtype.
DNA Methylation
DNA methylation (Infinium HumanMethylation450;
Illumina) data were available for 124 black cases and 517
Key Points
Question What are the tumor biological differences in invasive
breast cancers from patients of African and European ancestry?
Findings In the cohort study from The Cancer Genome Atlas, a
racial disparity in breast cancer–free interval and distribution of
aggressive subtypes of breast cancers was detected. After taking
into account differences in prevalence of intrinsic subtypes,
modest molecular differences in gene expression, protein
expression, somatic mutations, and DNA methylation patterns
were observed, and most significantly, higher genetic contribution
to estrogen receptor–negative breast cancer was seen in black
patients than in white patients.
Meaning Biological differences between breast cancers in blacks
and whites may be linked to differences in the distribution of
germline genetic variants, and interventions to improve cancer risk
assessment and optimal use of more effective targeted therapies
have the potential to close the widening mortality gap between
black and white patients with breast cancer.
Results
Molecular Portraits of Breast Tumors by Race
In the TCGA cohort, there were 154 black patients of African
ancestry and 776 white patients of European ancestry. While
not population based, many of our findings were in line with
previous population-based research. For example, black pa-
tients were diagnosed at a younger age and were more likely
to have ER-negative or nonluminal subtypes of breast can-
cers (Table 1). After adjusting for age, black patients had a higher
odds of basal-like (odds ratio, 3.80; 95% CI, 2.46-5.87; P < .001)
and HER2-enriched (odds ratio, 2.22; 95% CI, 1.10-4.47;
P = .027) breast cancer subtypes than white patients, with the
luminal A subtype as the reference.
We identified 9232 genes (49.1%) differentially expressed
between black and white patients after adjusting for age and
batch effects (nominal P < .05). After adjusting for subtype, 142
genes had Bonferroni-adjusted P < .05 (eTable 2 in Supplement
1). The top 2 differentially expressed genes were LOC90784 (no
OMIM accession number to date) and CRYBB2 (OMIM 123620)
(Figure 1). Unsupervised clustering analysis of the 142 genes
identified a branch enriched for black patients in each sub-
type (eFigure 1 in Supplement 2, right). Using penalized logis-
tic regression, we developed a gene expression signature from
the 142 genes distinguishing breast tumor samples from blacks
and whites, with a cross-validation AUROC of 0.878.
We found 25 proteins differentially expressed between tu-
mors from blacks and whites after adjusting for age, batch, and
subtype (eTable 3 in Supplement 1). Expression of these pro-
teins can moderately distinguish black and white patients
(eFigure 2 in Supplement 2). Two proteins (caspase-8 and Src)
had FDRs less than 0.05, but only caspase-8 had P < .05 after
Bonferroni adjustment. A logistic regression model that in-
cluded the 2 proteins yielded an AUROC of 0.629 in the cross-
validation analysis.
We did not find any difference in the total number of mu-
tations per patient between blacks and whites. However, the
total number of CNA segments was higher in black patients
compared with white patients within the luminal A subtype
(eFigure 3 in Supplement 2). Comparing mutation frequen-
cies of the 68 recurrently mutated genes, 44 regions of gain
and 28 regions of loss, we found that 13 of them were signifi-
cantly different between the 2 races (Table 2 and eTable 4 and
eTable 5 in Supplement 1). Compared with white patients, black
white cases. Of 480 721 probes, we identified 13 811 cancer-
associated hypermethylation probes located within 1500 base 
pairs of a transcription start site and 9436 cancer-associated 
hypomethylation probes that overlapped with putative en-
hancer regions (eMethods in Supplement 2). We used linear 
regression models to identify race-specific DNA methylation, 
with adjustment for age, tumor purity, and subtype.
Survival Analysis
We used a disease-free survival definition that included all 
breast cancer–related events to define the breast cancer–free 
interval (BCFI).20 Events for BCFI were defined as locore-
gional recurrences, distant metastases, new primary tumors 
in the breast, or deaths from breast cancer. The BCFI was de-
fined as the time from the date of the initial pathological di-
agnosis to the date of the events defined above, the date of last 
contact, or the date of death. For BCFI analysis, 17 patients with 
stage IV cancer at diagnosis were excluded. Another 17 pa-
tients who died with tumor but without an indication of a de-
fined new tumor event were excluded for lack of informa-
tion, resulting in 896 patients for BCFI analysis. Overall 
survival was defined as the date of diagnosis to the date of last 
contact or death (in 930 patients). Because of a limited dura-
tion of follow-up, survival analysis may be underpowered to 
detect racial disparity, especially for ER-positive breast can-
cer. To compensate for this limitation, we also calculated the 
PAM50-based risk of recurrence score,15 which estimates the 
biological potential of recurrence.
The Kaplan-Meier method was used to generate survival 
curves. We fit a series of Cox proportional hazards regression 
models, starting from a model with race only, then a multi-
variable model adjusting for age and American Joint Commit-
tee on Cancer stage, then subtypes, and then further adjust-
ing for molecular features (gene expression, protein expression, 
or mutation) that were differentially present between blacks 
and whites. Only molecular features associated with BCFI in 
Cox proportional hazards regression models were considered 
potential mediators.
Germline Variants
DNA from germline samples was hybridized to arrays (SNP 
Array 6.0; Affymetrix) to genotype single-nucleotide poly-
morphisms (SNPs). Of 93 breast cancer susceptibility loci 
identified in previous genome-wide association studies,21-25 
a total of 24 were genotyped. For the remaining SNPs, we con-
ducted imputation analysis using IMPUTE2 software,26 and 65 
SNPs could be imputed reliably (imputation score >0.7; mean, 
0.97). Therefore, a total of 89 SNPs were analyzed in this study. 
First, we compared SNP allele frequencies of these 89 SNPs 
between racial groups using Fisher exact test, and we deter-
mined if they varied by subtype after adjusting for race using 
logistic regression. Second, because the power for assessing 
individual SNPs was limited in the TCGA data set, we derived 
polygenetic risk scores (PRSs) for ER-positive and ER-
negative breast cancers to investigate the combined effects of 
89 SNPs using the following equation:
PRS=β1χ1+β2χ2+…+βκχκ+βnχn,
where βκ is the per-allele log odds ratio for breast cancer as-
sociated with risk alleles published previously23-25 and where 
χκ is the number of risk alleles (0, 1, or 2) for the kth SNP. Third, 
because many breast cancer susceptibility loci are yet to be 
identified, we tried to extract breast cancer subtype–related 
information using all genetic variants on Affymetrix arrays. 
With a mixed-effects model implemented in GCTA,27 we es-
timated subtype heritability. The phenotype in the mixed-
effects model is a simplified subtype (basal vs nonbasal). To 
increase statistical power, we also estimated the heritability 
of ESR1 and ERBB2 gene expression, 2 genes that are impor-
tant components of the PAM50 subtypes.
patients had a higher proportion of TP53 (OMIM 191170) mu-
tations (51.7% vs 31.3%) and 8q24.21/MYC (OMIM 190080) am-
plification (30.9% vs 20.4%) and a lower proportion of PIK3CA
(OMIM 171834) mutations (23.7% vs 35.6%). However, after ad-
justing for subtype, no mutations and only 4 CNAs (11q23.1 de-
letion, 21q21.1 deletion, 8p12 amplification, and 12q15 ampli-
fication) remained statistically significant, with slightly higher
frequencies in blacks.
We identified 9 hypermethylated DNA methylation probes
significantly associated with race after adjusting for age, tu-
mor purity, and subtype (multiple testing adjusted P < .001).
The DNA methylation levels of all 9 probes were higher in
blacks (eFigure 4 in Supplement 2). Of the hypomethylated
enhancer probes, 7 were significantly associated with race
after adjusting for age, tumor purity, and subtype (multiple
testing adjusted P < .001). The DNA methylation levels were
lower in black patients than in white patients, suggesting that
enhancers at these loci may be more active in black patients
(eFigure 5 in Supplement 2).
Figure 1. Plots of the CRYBB2 and LOC90784 Genes and Race-Enriched
Gene Expression Signature Estimated Using a Penalized Regression


























































Basal HER2 Luminal A Luminal B Normal
Race-enriched gene expression signatureC
All comparisons between black patients and white patients within each subtype
were statistically significant (P < .001 for all tests) except HER2-enriched
subtype for the LOC90784 gene (P = .017).





(n = 154) P Value
Age at diagnosis,
mean (SD), y
59.51 (13.11) 55.66 (13.01) .0009b
Sex, No. (%)
Female 768 (99.0) 151 (98.1)
.40
Male 8 (1.0) 3 (1.9)
PAM50 subtype, No. (%)
Luminal A 432 (55.7) 52 (33.8)
<.0001
Luminal B 161 (20.7) 27 (17.5)
HER2 44 (5.7) 12 (7.8)
Basal 114 (14.7) 56 (36.4)
Normal 24 (3.1) 7 (4.5)
ER, No. (%)
Positive 597 (76.9) 94 (61.0)





Positive 519 (66.9) 79 (51.3)





Positive 110 (14.2) 20 (13.0)
.80cNegative 648 (83.5) 129 (83.8)
Indeterminate
or not available
18 (2.3) 5 (3.2)
AJCC stage,
No./total No. (%)
I 138/762 (18.1) 28/151 (18.5)
.56
II 424/762 (55.6) 91/151 (60.3)
III 186/762 (24.4) 29/151 (19.2)









Abbreviations: AJCC, American Joint Committee on Cancer; ER, estrogen
receptor; PR, progesterone receptor.
a Some values do not sum to heading totals because of missing data.
b Wilcoxon rank sum test. All other comparisons are by Fisher exact test.
c Statistical tests were performed using counts of positive and negative cases
only.
Breast Cancer Recurrence and Survival by Race
During a median follow-up of 29 months, 81 BCFI recurrence
events occurred. There was a significant difference in BCFI
between blacks and whites (hazard ratio [HR], 1.67; 95% CI,
1.02-2.74; P = .043), with the difference most pronounced in
basal-like cancers or TNBCs (Figure 2, A-C). By contrast, blacks
had a higher PAM50 risk of recurrence score than whites, with
the difference most pronounced in non–basal-like cancers or
non-TNBCs (Figure 2, D-F). In the multivariable Cox propor-
tional hazards regression model adjusting for age and Ameri-
can Joint Committee on Cancer stage, blacks exhibited a sig-
nificantly worse outcome (HR, 1.90; 95% CI, 1.14-3.16; P = .014).
Further adjusting for subtype, the HR for race was reduced
slightly (HR, 1.73; 95% CI, 1.02-2.95; P = .043). We found more
racial differences in BCFI outcomes in basal-like breast can-
cer (HR, 2.36) than in nonbasal subtypes (HR, 1.28), although
none reached statistical significance due to limited events
within each subgroup (eTable 6 in Supplement 1).
The TP53 mutation was a positive predictor for recur-
rence (age- and stage–adjusted HR, 2.04; 95% CI, 1.29-3.22;
P = .002), and TP53 mutation frequency varied between blacks
and whites. The racial difference in BCFI remained statisti-
cally significant after adjusting for TP53 mutation status (HR,
2.10; 95% CI, 1.22-3.61; P = .007). The racial-enriched gene ex-
pression signature was prognostic across all patients (age and
stage–adjusted HR, 2.06; 95% CI, 0.95-4.46; P = .066); after
adding it to the model, the HR for race was reduced to 1.56 (95%
CI, 0.60-4.02; P = .36). The 2 most significantly differentially
expressed proteins (caspase-8 and Src), the PIK3CA muta-
tion, MYC amplification, and the 4 CNAs with different fre-
quencies between racial groups were not prognostic factors for
BCFI. Race was not associated with overall survival (eFigure
6 in Supplement 2). However, blacks with basal-like subtype
or TNBCs trended toward worse overall survival compared with
whites in subgroup analyses.
Germline Variants and the Heritability
of Breast Cancer Subtypes
We found significant allele frequency differences between
blacks and whites for 76 of 89 breast cancer susceptibility SNPs
in case-only analyses (eTable 7 in Supplement 1). After adjust-
ing for race, 4 SNPs were significantly associated with intrin-
sic subtype (eTable 8 in Supplement 1). The risk allele (T) of
SNP rs10069690 in TERT was higher in blacks than whites and
was associated with a higher odds of basal-like relative to lu-
minal A subtype breast cancer, which is consistent with
studies11,24 showing that rs10069690 was associated with ER-
negative breast cancer. Two SNPs (rs10069690 and rs7726159)
in TERT were associated with a lower odds of HER2-enriched
relative to luminal A subtype breast cancer. The risk allele (C)
of rs11814448 was a common allele in blacks but was rare in
whites, and it was associated with a lower odds of luminal B
subtype tumors. In contrast, the risk allele (A) of SNP
rs34084277 in BABAM1 (OMIM 612766) was lower in blacks
than whites, and it was associated with a higher odds of basal-
like compared with luminal A subtype breast cancer, a find-
ing consistent with previous genome-wide association stud-
ies showing that variants in the BABAM1 gene were associated
with ER-negative breast cancer.28 To summarize the com-
bined effect of 89 SNPs and understand how allele frequency
differences between blacks and whites in these common vari-
ants contribute to racial differences in subtype distribution,
we calculated breast cancer PRSs. We found that blacks had
higher ER-positive and ER-negative PRSs than whites, and the
racial difference in ER-negative PRSs was even larger (Figure 3),
suggesting that breast cancer (especially ER-negative breast
cancer) in blacks has a greater genetic contribution than in
whites.
In a heritability analysis of breast cancer subtype, we
found that 43.6% (SE, 24.5%; P = 1.5 × 10−14) of subtype varia-
tion can be explained by genome-wide germline variants. We







TP53 61/118 (51.7) 234/748 (31.3) 2.5 × 10−5 .85
PIK3CA 28/118 (23.7) 266/748 (35.6) .012 .60
FBXW7 5/118 (4.2) 9/748 (1.2) .031 .10
Deletion
8p23/CSMD1 22/152 (14.5) 66/759 (8.7) .035 .41
13q14/RB1 13/152 (8.6) 31/759 (4.1) .035 .37
11q23.1 6/152 (3.9) 10/759 (1.3) .037 .023
21q21.1 5/152 (3.3) 8/759 (1.1) .050 .031
Amplification
8q24.21/MYC 47/152 (30.9) 155/759 (20.4) .0072 .44
8p12 20/152 (13.2) 43/759 (5.7) .0024 6.4 × 10−4
8q11 16/152 (10.5) 45/759 (5.9) .049 .14
19q12/CCNE1 14/152 (9.2) 27/759 (3.6) .0046 .25
5p15/TERT 10/152 (6.6) 22/759 (2.9) .049 .46
12q15/MDM2 10/152 (6.6) 21/759 (2.8) .026 .011
a Genes after virgules are putative
oncogenic drivers or fragile sites
located within GISTIC peaks.
Accession numbers for the genes
are given in the text except for the
following: FBXW7 (OMIM 606278),
CSMD1 (OMIM 608397), RB1 (OMIM
604041), CCNE1 (OMIM 123837),
and MDM2 (OMIM 164785).
b Fisher exact test.
c Adjusted for PAM50 subtype.











































White (60 of 745)












































































Breast cancer–free interval, by gene-expression subtypeB
White (10 of 110)
Basal (P = .041)
Black (11 of 55)
White (50 of 634)
Nonbasal (P = .70)














































































Breast cancer–free interval, by IHC subgroupC
White (10 of 101)
TNBC (P = .059)
Black (10 of 49)
White (44 of 605)
Non-TNBC (P = .75)





















The survival analyses were performed using all follow-up time, although we plotted the curves for the first 10 years only. Shown are all patients (A), patients with
basal and nonbasal tumors (B), patients with triple-negative breast cancer (TNBC) and non-TNBC tumors (C), PAM50 risk of recurrence score (ROR-S) for all
patients (D), patients with basal and nonbasal tumors (E), and patients with TNBC and non-TNBC tumors (F). HR indicates hazard ratio; IHC, immunohistochemistry.
estimated the heritability of ESR1 (OMIM 133430) and ERBB2/
HER2 (OMIM 164870) gene expression as continuous vari-
ables and found the heritability of ESR1 to be 39.8% (SE,
16.0%; P = 1.3 × 10−14) and the heritability of ERBB2/HER2 to
be 17.3% (SE, 16.1%; P = .098). The ER-positive PRS built from
89 known susceptibility variants was higher in blacks than in
whites (difference, 0.24; P = 2.3 × 10−5), while the ER-
negative PRS was much higher in blacks than in whites (dif-
ference, 0.48; P = 2.8 × 10−11).
Discussion
In the first ancestry-based comprehensive analysis of mul-
tiple platforms of genomic and proteomic data of its kind to
date, we found significant molecular differences between in-
vasive breast cancers from genomically defined black and white
patients. Black patients were more likely to have basal-like and
ERBB2-enriched subtypes and less likely to have the luminal
A subtype than white patients. While most tumor genomic dif-
ferences between races can be captured by subtype, we found
a modest number of genomic features, including gene expres-
sion (n = 142), protein (n = 1), DNA copy number (n = 4), and
DNA methylation (n = 16), that were different between these
ancestry groups after adjusting for subtype.
We found a higher risk of recurrence for black patients rela-
tive to white patients, in particular for basal-like cancers or
TNBCs. Blacks had a higher PAM50 risk of recurrence score than
whites, especially for non–basal-like or non-TNBC breast can-
cer subtypes. These seemingly perplexing findings may re-
flect heterogeneous tumor biology: basal-like breast cancer has
rapid recurrence, so racial disparity in outcome can be cap-
tured in TCGA, which has a limited duration of follow-up, while
non–basal-like breast cancer has a longer time to recurrence.
The higher risk of recurrence for black patients relative to white
patients was attenuated after taking into account subtype and
was further reduced after adjusting for the race-specific gene
expression signature; it should be noted that this signature cor-
relates highly with ancestry, so collinearity existed. Several in-
vestigations have examined gene expression by race in breast
cancer: all studies29-34 except one35 found race-specific gene
expression patterns. Results from these studies are not en-
tirely consistent because of variable sample sizes and differ-
ing analytical methods. However, one gene that has been con-
sistently found to be higher in tumors from blacks than from
whites is the CRYBB2 gene.30-32,34 We showed that CRYBB2 ex-
pression was higher in black patients than in white patients
within each breast cancer subtype. Expression of CRYBB2 was
also found to be higher in normal breast tissue from blacks than
those from whites.31,34 Furthermore, CRYBB2 had higher ex-
pression in prostate cancer and colorectal cancer from black
Americans compared with white Americans.36,37 Taken to-
gether, these findings indicate that CRYBB2 is likely a true race-
specific gene, and its differential expression by race is likely
due to genetic background via expression quantitative trait loci
regulation. We conducted Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analysis of the 142 genes differen-
tially expressed between blacks and whites and found an en-
richment in ether lipid (P = .023) and alpha-linolenic acid
(P = .049) metabolic pathways. Such race-differential expres-
sion in lipid-metabolizing genes could be due to expression
quantitative trait loci regulation or may reflect differences in the
nutritional status or obesity rates between blacks and whites.38,39
We estimated that more than 40% of the variation in in-
trinsic breast cancer subtype can be explained by inherited
germline variants (known and unknown), suggesting that a sig-
nificant proportion of racial differences in subtype frequen-
cies are due to genetic factors. This finding is supported by pre-
vious studies11,28,40 in which predisposing germline variants
varied in frequency by race. The heritability of ESR1 was higher
than that of ERBB2/HER2, which extends previous observa-
tions that the ER-positive proportion varies widely across popu-
lations, while the ERBB2-positive proportion does not.10,41 For
known breast cancer susceptibility loci, most SNPs showed dif-
ferent allele frequencies between blacks and whites. We used
PRSs to summarize the combined effect of 89 known germ-
line variants and found that differences in allele frequencies
between blacks and whites can explain racial differences in the







–1.5 –1.0 –0.5 0 0.5 1.0 1.5
0










Black (mean [SD] PRS, 0.22 [0.51])
White (mean [SD] PRS, –0.02 [0.51])ER-positive patientsA
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Black (mean [SD] PRS, 0.44 [0.40])
White (mean [SD] PRS, –0.03 [0.44])ER-negative patientsB
P = 2.3 × 10-5 P = 2.8 × 10-11
Polygenic risk scores were calculated based on allele frequencies of 89 genetic variants and log odds ratios of 89 genetic variants for estrogen receptor (ER)–positive
and ER-negative breast cancers obtained from the literature.
distribution of subtypes, with blacks having a much higher PRS
for ER-negative breast cancer. Taken together, these findings
underscore the need for larger genetic epidemiological stud-
ies to identify additional biological factors that contribute to
racial frequency differences in breast cancer subtypes.
This comprehensive assessment of multiple omics data
types, including somatic mutations, CNAs, gene expression,
protein expression, DNA methylation, and germline variants,
identified important differences between breast cancers from
black and white patients. Compared with previous analyses of
TCGA breast cancer data, we included 154 black women, up-
dating the data sets presented previously in studies by Keenan
et al42 (n = 105) and Stewart et al29 (n = 53). The survival analy-
sis in our study provided a more stable assessment of racial
disparity because it included more events (81 vs 34) than the
previous analysis.42 We also used genomically determined race
to avoid possible misclassification and to eliminate missing data
in the self-reported race variable.
Limitations
The present study has some limitations. First, TCGA cohort con-
sists of convenience samples, so it may not represent a gen-
eral breast cancer patient population. Nonetheless, most of our
findings are similar to previous publications with respect to
the frequency differences and outcomes of blacks with basal-
like cancers or TNBCs.5-10,43 Second, a short follow-up time and
unclear definition of cause of death may have affected the in-
vestigation of racial disparity in cancer recurrence. Third, so-
cioeconomic and environmental factors were not available in
TCGA, so their contribution to racial disparity could not be
evaluated. Fourth, TCGA may not have sufficient power to test
racial differences in each breast cancer subtype because strin-
gent multiple testing procedures need to be taken.
Conclusions
In summary, this study demonstrated that there are biologi-
cal differences between breast cancers in black patients and
white patients that are linked to genetic ancestry broadly
and to specific inherited gene variants. Future studies are
warranted to investigate genetic and nongenetic factors that
contribute to heterogeneity in the development of distinct
breast cancer subtypes, as well as how these factors influ-
ence response to therapy and survival outcomes in diverse
populations.
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